- Home
- RNP vs COLL Comparison
RNP vs COLL Comparison
Compare RNP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.7M | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNP | COLL |
|---|---|---|
| Price | $19.51 | $48.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.50 |
| AVG Volume (30 Days) | 117.6K | ★ 515.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | N/A | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ N/A | $29.92 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $15.52 | $23.23 |
| 52 Week High | $21.27 | $49.16 |
Technical Indicators
Market Signals| Indicator | RNP | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 69.80 |
| Support Level | $19.27 | $47.86 |
| Resistance Level | $20.67 | $49.16 |
| Average True Range (ATR) | 0.27 | 1.29 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 16.88 | 87.45 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.